Pharming Group (OTCMKTS:PHGUF) Sees Large Volume Increase – Time to Buy?

Shares of Pharming Group NV (OTCMKTS:PHGUF) saw unusually-high trading volume on Tuesday . Approximately 20,000 shares traded hands during mid-day trading, an increase of 203% from the previous session’s volume of 6,591 shares.The stock last traded at $1.24 and had previously closed at $1.6350.

Pharming Group Price Performance

The stock has a market capitalization of $832.13 million, a PE ratio of 62.03 and a beta of 0.55. The firm’s 50 day simple moving average is $1.58 and its 200 day simple moving average is $1.65. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.59 and a quick ratio of 2.03.

Pharming Group (OTCMKTS:PHGUF) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. Pharming Group had a net margin of 3.30% and a return on equity of 4.68%. The company had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.